Colorectal Cancer Clinical Trial
Official title:
A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma
Verified date | November 2019 |
Source | Hoffmann-La Roche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase III, multicenter, open-label, three-arm, randomized study in participants with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at least two prior regimens of cytotoxic chemotherapy for metastatic disease. The study compares regorafenib, a standard of care therapy in this setting, to cobimetinib plus atezolizumab and atezolizumab monotherapy.
Status | Completed |
Enrollment | 363 |
Est. completion date | December 26, 2018 |
Est. primary completion date | March 9, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Disease-specific inclusion criteria: - Histologically confirmed adenocarcinoma originating from the colon or rectum (Stage 4 American Joint Committee on Cancer [AJCC] 7th edition) - Experienced disease progression or was intolerant to at least two systemic chemotherapy regimens for metastatic colorectal cancer that must have included fluroropyrimidines, irinotecan, and oxaliplatin; adjuvant regimen can be considered as one chemotherapy regimen for metastatic disease if the participant had disease recurrence within 6 months of completion; disease progression must have occurred within 3 months of the last systemic therapy administration General inclusion criteria: - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Anticipated life expectancy greater than or equal to (>=) 3 months - Adequate hematologic and end organ function - Women of childbearing potential must agree to appropriately use an effective form of contraception (failure rate of less than [<] 1 percent [%] per year) during the treatment period, within 5 months after the last dose of atezolizumab, and within 3 months after the last dose of cobimetinib and regorafenib - Men must agree not to donate sperm or have intercourse with a female partner without using appropriate barrier contraception during the treatment period and for 3 months after the last dose of either cobimetinib or regorafenib - Provide an archival or newly obtained tumor tissue sample Exclusion Criteria: - After the approximate 5% cap for microsatellite (MSI)-high participants is reached, only MSI-stable participants will be eligible - Once the 50% cap for wild-type RAS has been reached, only extended RAS-mutant participants will be eligible - Major surgery or radiotherapy within 21 days prior to Cycle 1 Day 1 or anticipation of needing such procedure while receiving study treatment - Treatment with any anti-cancer agent within 14 days prior to Cycle 1 Day 1 - Uncontrolled tumor-related pain. Participants requiring narcotic pain medication must be on a stable regimen at study entry - Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage more than once every 28 days. Indwelling drainage catheters (e.g., PleurX®) are allowed - Active or untreated central nervous system (CNS) metastases are excluded - Prior therapy with any cancer immunotherapy, MEK inhibitor, or regorafenib - Participants with active malignancy (other than CRC) or a prior malignancy within the past 3 years are excluded. Participants with completely resected cutaneous melanoma (early stage), basal cell carcinoma, cutaneous squamous cell carcinoma, cervical carcinoma in-situ, breast carcinoma in-situ, and localized prostate cancer are eligible - Unstable angina, new onset angina within last 3 months, myocardial infarction within last 6 months and current congestive heart failure New York Heart Association Class II or higher - Left ventricular ejection fraction (LVEF) below institutional lower limit of normal or below 50%, whichever is lower - Poorly controlled hypertension, defined as a blood pressure consistently above 150/90 millimeters of Mercury (mmHg) despite optimal medical management - Human immunodeficiency virus (HIV) infection - Active tuberculosis infection - Severe infections within 2 weeks prior to Cycle 1 Day 1 - Active or chronic viral hepatitis B or C infection - History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for central serous retinopathy, retinal vein occlusion, or neovascular macular degeneration - Participants will be excluded if they currently have any of the risk factors as defined in the study protocol for retinal vein occlusion - History of autoimmune disease - History of idiopathic pulmonary fibrosis, organizing pneumonia, bronchiolitis obliterans, drug-induced pneumonitis, or idiopathic pneumonitis - History of organ transplantation including allogeneic bone marrow transplantation - Inability to swallow medications - Malabsorption condition that would alter the absorption of orally administered medications - Pregnant, lactating, breastfeeding, or intending to become pregnant during the study - Administration of a live, attenuated vaccine within 4 weeks before randomization or anticipation of a live attenuated vaccine will be required during the study |
Country | Name | City | State |
---|---|---|---|
Australia | Monash Medical Centre; Oncology | Clayton | Victoria |
Australia | Peninsula and South Eastern Haematology and Oncology Group | Frankston | Victoria |
Australia | Austin Health; Cancer Clinical Trial Centre | Heidelberg | Victoria |
Australia | Port Macquarie Base Hospital;North Coast Cancer Institute | Port Macquarie | New South Wales |
Australia | Northern Cancer Institute | St Leonards | New South Wales |
Australia | Sydney Adventist Hospital; Clinical Trial Unit | Sydney | New South Wales |
Belgium | Imeldaziekenhuis | Bonheiden | |
Belgium | Cliniques Universitaires St-Luc | Bruxelles | |
Belgium | GHdC Site Notre Dame | Charleroi | |
Belgium | AZ Groeninge | Kortrijk | |
Belgium | UZ Leuven Gasthuisberg | Leuven | |
Canada | Tom Baker Cancer Centre-Calgary | Calgary | Alberta |
Canada | Cross Cancer Institute; Clinical Trials | Edmonton | Alberta |
Canada | Hopital du Sacre-Coeur | Montreal | Quebec |
Canada | McGill University Health Center, Cedar Cancer Center | Montreal | Quebec |
Canada | The Ottawa Hospital | Ottawa | Ontario |
Canada | CHU de Québec | Quebec City | Quebec |
Canada | Sunnybrook Health Sciences Centre | Toronto | Ontario |
Canada | BCCA-Vancouver Cancer Centre | Vancouver | British Columbia |
Hong Kong | Queen Mary Hospital; Dept. of Clinical Oncology | Hong Kong | |
Hong Kong | Tuen Mun Hospital; Clinical Oncology | Hong Kong | |
Hong Kong | Prince of Wales Hosp; Dept. Of Clinical Onc | Shatin | |
Italy | Istit. Naz. per la Ricerca sul Cancro - Az. Osped. S. Martino | Genova | Liguria |
Italy | Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia | Milano | Lombardia |
Italy | Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1 | Milano | Lombardia |
Italy | A.O. Universitaria Policlinico Di Modena; Oncologia | Modena | Emilia-Romagna |
Italy | Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia Medica | Napoli | Campania |
Italy | A.O. Universitaria Pisana; Oncologia | Pisa | Toscana |
Italy | IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia | San Giovanni Rotondo | Puglia |
Korea, Republic of | National Cancer Center | Gyeonggi-do | |
Korea, Republic of | Chonnam National University Hwasun Hospital | Jeollanam-do | |
Korea, Republic of | Asan Medical Center - Oncology | Seoul | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Yonsei University Health System/Severance Hospital | Seoul | |
Poland | Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy | Bydgoszcz | |
Poland | Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii | Gdansk | |
Poland | Szpitale Pomorskie Sp. z o. o. | Gdynia | |
Poland | Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny Kliniki Onkologii | Krakow | |
Poland | Woj.Wielospecjalistyczne Centrum Onkologii i Traumatologii; Oddz.Hematologii Pododz.Chemioterapii | Lodz | |
Russian Federation | Arkhangelsk Regional Clinical Oncology Dispensary | Arkhangelsk | |
Russian Federation | N.N.Burdenko Main Military Clinical Hospital; Oncology Dept | Moscow | |
Russian Federation | BHI of Omsk region Clinical Oncology Dispensary | Omsk | |
Spain | Hospital Univ Vall d'Hebron; Servicio de Oncologia | Barcelona | |
Spain | Hospital Clinico San Carlos; Servicio de Oncologia | Madrid | |
Spain | Hospital Ramon y Cajal; Servicio de Oncologia | Madrid | |
Spain | Hospital Universitario 12 de Octubre; Servicio de Oncologia | Madrid | |
Spain | Hospital de Navarra; Servicio de Oncologia | Navarra | |
Spain | Hospital Clínico Universitario de Valencia; Servicio de Oncología | Valencia | |
United Kingdom | Birmingham Heartlands Hospital; Dept of Oncology | Birmingham | |
United Kingdom | Royal Marsden Hospital - Fulham; Oncology Department | London | |
United Kingdom | The Christie; GI Research Office | Manchester | |
United Kingdom | Churchill Hospital; Department of Oncology | Oxford | |
United Kingdom | Queen's Hospital | Romford | |
United Kingdom | Weston Park Hospital; Cancer Clinical Trials Centre | Sheffield | |
United Kingdom | Royal Marsden Hospital; Dept of Medical Oncology | Sutton | |
United States | SCRI Tennessee Oncology Chattanooga | Chattanooga | Tennessee |
United States | City of Hope Comprehensive Cancer Center | Duarte | California |
United States | North Shore Hem Onc Associates | East Setauket | New York |
United States | Southdale Cancer Clinic U of M Medical Center, Fairview- Edina | Edina | Minnesota |
United States | Florida Cancer Specialists; SCRI | Fort Myers | Florida |
United States | Ingalls Cancer Research Center | Harvey | Illinois |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy) | Jacksonville | Florida |
United States | Sarah Cannon Research Inst. | Nashville | Tennessee |
United States | Yale Cancer Center; Medical Oncology | New Haven | Connecticut |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | INTEGRIS Cancer Inst of OK | Oklahoma City | Oklahoma |
United States | University of Pittsburgh Cancer Institute; Division of Medical Oncology | Pittsburgh | Pennsylvania |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Florida Cancer Specialists. | Saint Petersburg | Florida |
United States | Medical Oncology Associates | Spokane | Washington |
United States | Georgetown University | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
United States, Australia, Belgium, Canada, Hong Kong, Italy, Korea, Republic of, Poland, Russian Federation, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Survival (OS) | Overall survival is defined as the time (in months) between the date of randomization and the date of death due to any cause. Participants who were not reported as having died at the date of analysis were censored at the date when they were last known to be alive. Participants who did not have post-baseline information were censored at the date of randomization + 1 day. Median OS was estimated by Kaplan-Meier method and 95% CI was assessed using the method of Brookmeyer and Crowley. | From randomization up to death due to any cause (up to approximately 20 months) | |
Secondary | Progression-Free Survival (PFS) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression. Participants who did not have post-baseline information were censored at the date of randomization + 1 day. Median OS was estimated by Kaplan-Meier method and 95% CI was assessed using the method of Brookmeyer and Crowley. | From randomization up to disease progression or death due to any cause (up to approximately 20 months) | |
Secondary | Percentage of Participants With Investigator-Assessed Objective Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.1 | PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). Objective response and its 95% CI were calculated using the Clopper-Pearson method. | From randomization up to death due to any cause (up to approximately 20 months) | |
Secondary | Duration of Response (DOR) According to RECIST Version 1.1 | DOR is defined as the period measured from the date of the first occurrence of a CR or PR (whichever status is recorded first) until the first date that progressive disease or death is documented. Disease progression was determined on the basis of investigator assessment with use of RECIST v1.1. Median DOR was estimated using the Kaplan-Meier method, and the 95% CI was calculated using the method of Brookmeyer and Crowley. | From first occurrence of CR or PR up to disease progression or death due to any cause (up to approximately 20 months) | |
Secondary | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire (EORTC QLQ-C30) Physical Functioning Sub-scale Score | The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning. | Baseline, end of the study (up to approximately 2.5 years) | |
Secondary | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire (EORTC QLQ-C30) Global Quality of Life Sub-scale Score at the End of the Study | The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning. | Baseline, end of the study (up to approximately 2.5 years) | |
Secondary | Percentage of Participants With Adverse Events (AEs) | Baseline, end of the study (up to approximately 2.5 years) | ||
Secondary | Plasma Concentration of Cobimetinib | Predose (0 hours) and 3 to 6 hours after dose on Day 15 of Cycles 1 and 4 (1 cycle = 28 days) (up to approximately 2.5 years). | ||
Secondary | Serum Concentration of Atezolizumab | Pre-infusion (0 hours) on Day 1 of Cycles 1 to 4; 30 minutes post-infusion on Day 1 of Cycles 1 and 4; pre-infusion (0 hours) on Day 1 of Cycle 8 and every 8 cycles thereafter; at treatment discontinuation; 120 days after treatment discontinuation (up to approximately 2.5 years) (1 cycle = 28 days) | Pre-infusion (0 hours) on Day 1 of Cycle 1 up to approximately 2.5 years. Detailed time frame is explained in the outcome measure description field. | |
Secondary | Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab | Pre-infusion (0 hours) on Day 1 of Cycles 1 to 4, 8, and every 8 cycles thereafter; at treatment discontinuation; 120 days after treatment discontinuation (up to approximately 2.5 years) (1 cycle = 28 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |